Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.59 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.49 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636725 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL18459144 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL7915032 | 0.82 | ALDH1A1 (0.56) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL3518114 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL6590884 | 0.80 | KDM5B (0.58) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL6779214 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL26081739 | 0.79 | KDM4E (0.61) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL24578777 | 0.76 | MDM4 (0.40) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL8269963 | 0.76 | DHODH (0.40) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL3455631 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4362876-A | Preparation of dihydroxyquinoline and certain derivatives | THE SHERWIN-WILLIAMS COMPANY (US) | 1982-12-07 | — | — | US | claimed |
| US-10376504-B2 | Substituted quinolinones as PDE9 inhibitors | Merck, Sharp & Dohme Corp. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10370336-B2 | Phenyl-cyanoquinolinone PDE9 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370337-B2 | Oxy-cyanoquinolinone PDE9 inhibitors | Merck, Sharp & Dohme Corp. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370337-B2 | Oxy-cyanoquinolinone PDE9 inhibitors | Merck, Sharp & Dohme Corp. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180258046-A1 | OXY-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180214439-A1 | AZA-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180208557-A1 | PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2017019726-A1 | OXY-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019726-A1 | OXY-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019723-A1 | AZA-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019724-A1 | PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2006034491-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034512-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006034512-A2 | PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-0252350-B1 | 3-CYANOQUINOLINE DERIVATIVES | BASF Aktiengesellschaft (DE) | 1991-01-02 | — | — | EP | disclosed |
| US-4927935-A | 3-cyanoquinoline derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1990-05-22 | — | — | US | disclosed |
| EP-0252350-A1 | 3-Cyanoquinoline derivatives | BASF Aktiengesellschaft (DE) | 1988-01-13 | — | — | EP | disclosed |
| US-4362876-A | Preparation of dihydroxyquinoline and certain derivatives | THE SHERWIN-WILLIAMS COMPANY (US) | 1982-12-07 | — | — | US | disclosed |
| US-4362876-A | Preparation of dihydroxyquinoline and certain derivatives | THE SHERWIN-WILLIAMS COMPANY (US) | 1982-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208557-A1 | PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS | PDE9A, PDE5A, PDE2A | KDM4E 2100/4885ALDH1A1 1270/4885KMT2A 1594/4885 |
| US-10370336-B2 | Phenyl-cyanoquinolinone PDE9 inhibitors | PDE9A, PDE5A, PDE2A | KDM4E 2100/4885ALDH1A1 1270/4885KMT2A 1594/4885 |
| US-20180258046-A1 | OXY-CYANOQUINOLINONE PDE9 INHIBITORS | PDE9A, PDE2A, PDE5A | KDM4E 2185/4885ALDH1A1 1238/4885KMT2A 1887/4885 |
| US-10376504-B2 | Substituted quinolinones as PDE9 inhibitors | PDE9A, PDE5A, PDE2A | KDM4E 1135/4885ALDH1A1 898/4885KMT2A 779/4885 |
| US-20180214439-A1 | AZA-CYANOQUINOLINONE PDE9 INHIBITORS | PDE9A, PDE7B, PDE5A | KDM4E 1117/4885ALDH1A1 1097/4885KMT2A 614/4885 |
| US-10370337-B2 | Oxy-cyanoquinolinone PDE9 inhibitors | PDE9A, PDE2A, PDE5A | KDM4E 2185/4885ALDH1A1 1238/4885KMT2A 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.